Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rituximab/yttrium Y 90 ibritumomab tiuxetan

Known as: IDEC-Y2B8/MOAB IDEC-C2B8 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
PurposeThe aim of this study was to evaluate the safety, toxicity and therapeutic response of non-myeloablative… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
2001
2001
Mantle cell lymphoma (MCL) has a poor prognosis without cure; the median overall survival ranges only from 3 to 4 years… Expand
2001
2001
The chimeric monoclonal anti-CD20 antibody has been widely used for the treatment of relapsed or refractory low-grade B-cell non… Expand
Highly Cited
2000
Highly Cited
2000
Rituximab (IDEC-C2B8, Mabthera(R)) is a chimeric (human-mouse) monoclonal antibody (MoAb) against the B-cell specific CD20… Expand
Highly Cited
2000
Highly Cited
2000
Abstract.Dosimetry studies in patients with non-Hodgkin’s lymphoma were performed to estimate the radiation absorbed dose to… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Highly Cited
1998
Highly Cited
1998
SummaryIn this report we present a patient with B-cell chronic lymphocytic leukemia who developed an acute tumor lysis syndrome… Expand
  • figure 1
Highly Cited
1998
Highly Cited
1998
BACKGROUND In clinical trials in the USA, IDEC-C2B8 (a mouse-human chimeric anti-CD20 monoclonal antibody) has demonstrated high… Expand
Highly Cited
1998
Highly Cited
1998
Treatment with IDEC‐C2B8 (C2B8), the chimeric anti‐CD20 antibody, was shown in a phase I‐II study to be very effective for the… Expand
  • table I
  • figure 1
  • figure 2
  • figure 3
  • figure 4
1998
1998
  • C. McNeil
  • Journal of the National Cancer Institute
  • 1998
  • Corpus ID: 34256085
Researchers in December launched a new randomized trial for elderly patients with intermediate-grade nonHodgkin 's lymphoma (NHL… Expand
Highly Cited
1997
Highly Cited
1997
IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell-specific antigen CD20 expressed on non-Hodgkin's… Expand
  • table 1
  • table 2
  • table 3
  • figure 1